Evidence map›Paper›PMID 11413294›Full record

ArticleJournal of virology2001

Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles.

C L Day, A K Shea, M A Altfeld, D P Olson, S P Buchbinder, F M Hecht, E S Rosenberg, B D Walker, S A Kalams

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

C L DayPartners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA.
A K Shea
M A Altfeld
D P Olson
S P Buchbinder
F M Hecht
E S Rosenberg
B D Walker
S A Kalams
Harvard University · USMassachusetts General Hospital · US

Funding

PARTNERS/FENWAY/SHATTUCK CENTER FOR AIDS RESEARCHP30AI042851 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2000 to 2003
$5.7M
TCR GENE USAGE AND QUANTITATION OF HIV SPECIFIC CTLR01AI039966 · NIAID · VANDERBILT UNIVERSITY · PI KALAMS, SPYROS A · 1997 to 2006
$3.2M
HIV-1-SPECIFIC T CELL CLONESR01AI028568 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1989 to 2008
$1.9M
HIV-1 SPECIFIC T CELL CLONESR37AI028568 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1994 to 2003
$1.6M
NIAID NIH HHS AI28568NIAID NIH HHS AI39966NIAID NIH HHS AI42851NIAID NIH HHS AI50914NIAID NIH HHS P30 AI042851NIAID NIH HHS R01 AI028568NIAID NIH HHS R01 AI039966NIAID NIH HHS R37 AI028568
6 · The paper itself

Abstract

Cytotoxic T lymphocytes (CTL) target multiple epitopes in human immunodeficiency virus (HIV)-infected persons, and are thought to influence the viral set point. The extent to which HLA class I allele expression predicts the epitopes targeted has not been determined, nor have the relative contributions of responses restricted by different class I alleles within a given individual. In this study, we performed a detailed analysis of the CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7. The eight HIV-1-infected subjects studied included two subjects with acute HIV infection, five subjects with chronic HIV infection, and one long-term nonprogressor. Responses were heterogeneous with respect to breadth and magnitude of CTL responses in individuals of the same HLA type. Of the 27 tested epitopes that are presented by A2, A3, and B7, 25 were targeted by at least one person. However, there was wide variation in the number of epitopes targeted, ranging from 2 to 17. The A2-restricted CTL response, which has been most extensively studied in infected persons, was found to be narrowly directed in most individuals, and in no cases was it the dominant contributor to the total HIV-1-specific CTL response. These results indicate that HLA type alone does not predict CTL responses and that numerous potential epitopes may not be targeted by CTL in a given individual. These data also provide a rationale for boosting both the breadth and the magnitude of HIV-1-specific CTL responses by immunotherapy in persons with chronic HIV-1 infection.

Indexed as

HIV-1AllelesChronic DiseaseEpitopes, T-LymphocyteHistocompatibility Antigens Class IHIV InfectionsHLA-A1 AntigenHLA-A2 AntigenHLA-B7 AntigenHumansT-Lymphocytes, CytotoxicEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-A1 AntigenHLA-A2 AntigenHLA-B7 Antigen

Identifiers

PMID11413294
PMCPMC114350
OpenAlexW1992039355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.